Consuming alcohol while taking Urobak may cause symptoms such as flushing, increased heart beat, nausea, thirst, chest pain and low blood pressure (Disulfiram reaction).
SAFE IF PRESCRIBED
Urobak is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Urobak should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
Urobak may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Urobak should be used with caution in patients with kidney disease. Dose adjustment of Urobak may be needed. Please consult your doctor. Use of Urobak is not recommended in patients with severe kidney disease, who are unable to pass urine or have high creatinine levels.
Urobak should be used with caution in patients with liver disease. Dose adjustment of Urobak may be needed. Please consult your doctor. Use of Urobak is not recommended in patients with severe liver disease and active liver disease.
Urobak is an antibiotic that fights bacteria. It is used to treat and prevent uncomplicated urinary tract infections. It works by killing the bacteria that cause such disease. But, it will not treat a viral infection. Urobak should be taken in the dose and duration as advised by the doctor. You may take it with food to avoid nausea, which is a common side effect. It is better to have this medicine at the same time each day to get the most benefit and you should keep on taking this medicine for as long as you are prescribed it, even if your symptoms quickly improve. If you stop taking it too early the infection may return or worsen. Some people may develop side effects like nausea, vomiting, and diarrhea. These side effects are usually temporary and go away during treatment as your body adjusts to the medicine. Consult your doctor if these side effects bother you or do not go away. This medicine may turn your urine into dark yellow or brown color. But, this is normal and nothing to worry about. Before starting treatment with this medicine, you should tell your doctor if you are pregnant, breastfeeding or suffering from any liver, kidney or heart problems or if you are allergic to any antibiotic.
Uses of Urobak
- Bacterial infections of urinary tract
Side effects of Urobak
How to use Urobak
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Urobak is to be taken with food.
How Urobak works
Urobak is an antibiotic. It works by killing the bacteria in the urine that causes infection.
What if you forget to take Urobak?
If you miss a dose of Urobak, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
- Niftas Tablet SR treats and prevents uncomplicated urinary tract infections.
- Finish the prescribed course of the medicine, even if you start to feel better. Stopping it early may make the infection come back and harder to treat.
- Take it with food to avoid nausea, which is a common side effect.
- It can turn your urine a dark yellow or brown colour. This is normal and nothing to worry about.
- Do not take it for longer or more often than prescribed by your doctor.
Uncomplicated UTI, Urinary Tract Infection
Should be taken with food. Take w/ or immediately after meals. Sustained release macrocrystals indicated only for patients >12 years for acute UTIs (cystitis) caused by E coli or S saprophyticus
Oral Acute uncomplicated urinary tract infections Adult: 50-100 mg 4 times daily for 7 days or for 3 days after obtaining sterile urine. SR preparation: 100 mg bid for 7 days or for 3 days after obtaining sterile urine. Prophylaxis of uncomplicated urinary tract infections Adult: 50-100 mg at bedtime for up to 12 months.
Urinary Tract Infection >1 month 5-7 mg/kg/day PO divided q6hr for 7 days UTI prophylaxis: 1-2 mg/kg PO qHS or 2 divided doses >12 years 50-100 mg PO q6hr for 7 days or for 3 days after obtaining sterile urine SR preparation: 100 mg PO q12hr for 7 days or for 3 days after obtaining sterile urine Long-term prophylaxis/suppression: 50-100 mg PO at bedtime for up to 12 months
Loses effectiveness in patients with CrCl <60 mL/min due to inadequate urine concentration Monitor renal function; renally excreted; decreased renal function more likely in elderly
Severe renal impairment (anuria, oliguria, significantly elevated serum creatinine, CrCl <60 ml/min). Hypersensitivity to nitrofurans, G6PD deficiency, infants <3 mth. Pregnancy at term, during labour and delivery, or when the onset of labour is imminent.
Mode of Action
Nitrofurantoin interferes with cell metabolism and cell wall synthesis by inhibiting several enzyme systems including acetyl coenzyme A. It is bactericidal to most gram-positive and gram-negative urinary tract pathogens.
Elderly. Monitor hepatic and pulmonary function during prolonged therapy. Pre-existing pulmonary, hepatic, neurological, or allergic disorders, predisposition to peripheral neuropathy e.g. renal impairment, anaemia, DM, electrolyte imbalance, debility, vitamin B deficiency. Withdraw if signs of peripheral neuropathy occur. Lactation. Lactation: Enters breast milk; discontinue drug or do not nurse
Nausea, vomiting, anorexia, abdominal pain, diarrhoea; headache, drowsiness, vertigo, dizziness, nystagmus, benign intracranial hypertension; rash, urticaria, pruritus, fever, sialadenitis, angioedema, erythema multiforme, exfoliative dermatitis, pancreatitis, lupus-like syndrome, myalgia, arthralgia; acute pulmonary sensitivity reactions; megaloblastic anaemia, leucopenia, granulocytopenia or agranulocytosis, thrombocytopenia, aplastic anaemia, haemolytic anaemia (in G6PD-deficient patients); transient alopecia; brownish discolouration of urine. Potentially Fatal: Peripheral polyneuropathy, hepatotoxicity, anaphylaxis, Stevens-Johnson syndrome, interstitial pneumonitis, pulmonary fibrosis.
Reduced excretion with probenecid or sulfinpyrazone. Absorption reduced by magnesium trisilicate. Antagonistic effects with quinolone antibacterials. Reduced effects with carbonic anhydrase inhibitors or urinary alkalinisers.
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.